Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 08 01; 34(22):2602-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Breast Neoplasms
Disease-Free Survival
Female
Humans
Middle Aged
Nitriles
Postmenopause
Treatment Outcome
Triazoles

authors with profiles

Olwen Hahn